Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

LEASE AGREEMENTS (Tables)

LEASE AGREEMENTS (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of components of operating lease expense

For the years ended December 31, 2020 and 2019, the components of our operating lease expense was as follows (in thousands):


	Year Ended December 31,
	2020		2019
Fixed operating lease expense	$	5,360	$	5,248
Variable operating lease expense		926		745
Total operating lease expense	$	6,286	$	5,993

Schedule of supplemental information related to operating lease


	Year Ended December 31,
	2020		2019
Fixed operating lease expense	$	5,360	$	5,248
Variable operating lease expense		926		745
Total operating lease expense	$	6,286	$	5,993

Schedule of operating sublease information

For the years ended December 31, 2020 and 2019, we have the following operating sublease information (in thousands):


	Year Ended December 31,
	2020		2019
Fixed sublease expense	$	4,381	$	4,381
Variable sublease expense		962		829
Sublease income		(5,343)		(5,210)
Net	$	—	$	—

Schedule of future minimum lease payments

At December 31, 2020, future minimum lease payments and obligations under our noncancelable operating lease, net of expected sublease receipts, were as follows (in thousands):


	Operating		Sublease
For years ending December 31,	Lease		Receipts		Net
2021	$	10,082	$	(4,534)	$	5,548
2022		10,485		(4,716)		5,769
2023		877		(394)		483
Total minimum payments required	$	21,444	$	(9,644)	$	11,800